Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Women Infertility pipeline market report provides a comprehensive overview of the therapeutics under development for Women Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects.
Women Infertility Pipeline Drugs Market by Key Targets
In the Women Infertility pipeline drugs market, the key targets are Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype.
Key Targets in the Women Infertility Pipeline Drugs Market
For more target insights, download a free report sample
Key MoA in the Women Infertility Pipeline Drugs Market
Follicle Stimulating Hormone Receptor Agonist has the highest share in the Women Infertility Pipeline Drugs Market. The other key mechanisms of action are Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist.
Women Infertility Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Women Infertility Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Women Infertility pipeline drug market are oral, subcutaneous, intravenous, intramuscular, vaginal, parenteral, injection, intraarterial, intracavitary, and intrauterine. Oral has the maximum number of pipeline products.
Women Infertility Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Women Infertility Pipeline Drugs Market
The key molecule types in the Women Infertility pipeline drugs market are Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy. Small molecule has the maximum number of pipeline products.
Women Infertility Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Women Infertility Pipeline Drugs Market
Some of the major companies in the Women Infertility pipeline drugs market are Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd.
Women Infertility Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Women Infertility Pipeline Drugs Market Overview
Key Targets | Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype |
Key Mechanisms of Action | Follicle Stimulating Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist |
Key Routes of Administration | Oral, Subcutaneous, Intravenous, Intramuscular, Vaginal, Parenteral, Injection, Intraarterial, Intracavitary, and Intrauterine |
Key Molecule Types | Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy |
Major Companies | Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility
- The pipeline guide reviews pipeline therapeutics for Women Infertility by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Women Infertility
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amega Biotech
Anelleo Inc
Aprilbio Co Ltd
Aptorum Group Ltd
ASKA Pharmaceutical Holdings Co Ltd
Bayer AG
BCI Pharma SA
Beijing FuKangren Bio-pharm Tech Co Ltd
Beijing SL Pharmaceutical Co Ltd
Bharat Serums And Vaccines Ltd
Bol Pharma
Bopin (Shanghai) Biomedical Technology Co Ltd
Chugai Pharmaceutical Co Ltd
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Egret Therapeutics Inc
Eikonoklastes Therapeutics Inc
ElexoPharm GmbH
Endomet Biosciences Inc
Enteris BioPharma Inc
Eurofarma Laboratorios SA
Evestra Inc
Evotec SE
Ferring International Center SA
Ferring Pharmaceuticals Inc
Forendo Pharma Ltd
GeneScience Pharmaceuticals Co Ltd
Genome & Co
Glycotope GmbH
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hope Medicine Inc
Igenomix SL
Igyxos SA
Immunitor Inc
Insud Pharma
Ironwood Pharmaceuticals Inc
Isifer AB
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Medibiofarma SL
Mithra Pharmaceuticals SA
Mitsubishi Tanabe Pharma Corp
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Neuromagen Pharma Ltd
Nippon Shinyaku Co Ltd
NutriBand Inc
ObsEva SA
Oxolife SL
Pangen Biotech Inc
Park of Active Molecules
Pharmasyntez
Predictive Therapeutics LLC
PregLem SA
Reven Holdings Inc
Shandong TheraWisdom Biopharma Co Ltd
Shanghai Jing Ze Biotechnology Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
SYNG Pharmaceuticals Inc
Synokem Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Temple Therapeutics BV
TiumBio Co Ltd
Trophogen Inc
Unicohealth Pharma Co Ltd
ValiRx Plc
Viramal Ltd
Xbrane Biopharma AB
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Women Infertility pipeline drug market?
In the Women Infertility pipeline drugs market the key targets are Follicle Stimulating Hormone Receptor, Gonadotropin Releasing Hormone Receptor, Progesterone Receptor, Estrogen Receptor, Estradiol 17 Beta Dehydrogenase 1, Lutropin Choriogonadotropic Hormone Receptor, KiSS 1 Receptor, Oxytocin Receptor, Prostaglandin E Synthase, Prostaglandin E2 Receptor EP2 Subtype, and Prostaglandin E2 Receptor EP4 Subtype.
-
What are the key mechanisms of action in the Women Infertility pipeline drugs market?
In the Women Infertility pipeline drugs market the key mechanisms of action are Follicle Stimulating Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor Antagonist, Progesterone Receptor Agonist, Estrogen Receptor Agonist, Estradiol 17 Beta Dehydrogenase 1 Inhibitor, Lutropin Choriogonadotropic Hormone Receptor Agonist, KiSS 1 Receptor Agonist, Oxytocin Receptor Antagonist, Prostaglandin E Synthase Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Antagonist, and Prostaglandin E2 Receptor EP4 Subtype Antagonist.
-
What are the key routes of administration in the Women Infertility pipeline drugs market?
The key routes of administration in the Women Infertility pipeline drug market Oral, Subcutaneous, Intravenous, Intramuscular, Vaginal, Parenteral, Injection, Intraarterial, Intracavitary, and Intrauterine. Oral has the maximum number of pipeline products.
-
What are the key molecule types in the Women Infertility pipeline drugs market?
The key molecule types in the Women Infertility pipeline drug market are Small Molecule, Recombinant Protein, Synthetic Peptide, Fusion Protein, Biologic, Monoclonal Antibody, Protein, and Cell Therapy.
-
What are the major companies in the Women Infertility pipeline drugs market?
In the Women Infertility pipeline drugs market the major companies are Ferring International Center SA, Bayer AG, GeneScience Pharmaceuticals Co Ltd, Kissei Pharmaceutical Co Ltd, Daewoong Pharmaceutical Co Ltd, Evotec SE, Ferring Pharmaceuticals Inc, Forendo Pharma Ltd, Genome & Co, and Livzon Pharmaceutical Group Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.